Clinical studies have shown that anti-IL-23 antibodies (e.g., risankizumab) and anti-IL-17 antibodies (e.g., secukinumab) achieve significant efficacy in psoriasis and other Th17-mediated diseases. The gene discussed is IL17A; the disease is psoriasis.